Novo Nordisk beats third quarter and raises outlook

Novo Nordisk reported third quarter sales of 79.2 billion Danish kroner, ahead of estimates of 73.6 billion, and raised its full year outlook to growth of negative 2 percent to 2 percent at constant exchange rates.

Why it matters: The beat and the guidance raise are the first clear sign the Wegovy maker is regaining momentum after a year in which it fell behind Eli Lilly in the weight loss market, with sales of its Wegovy pill beating estimates.

Data as of CNBC report of November 4, 2026, read in full in this run, carrying the sales, operating profit and outlook figures against FactSet estimates, corroborated on the beat and the guidance raise by Reuters reporting of the same morning. Novo Nordisk's own quarterly report was not obtained in this run. Developing item.

Novo Nordisk reported third quarter sales of 79.2 billion Danish kroner (about $11.9 billion), up 4 percent year on year and ahead of FactSet estimates of 73.6 billion kroner, with adjusted operating profit of 31.7 billion kroner against 28.6 billion expected, CNBC reported. Sales of the company’s Wegovy pill beat estimates, though CNBC gave no separate figure for them.

The company raised its full year outlook for both adjusted revenue and operating profit growth to between negative 2 percent and 2 percent at constant exchange rates, from negative 6 percent to flat previously, an outlook it had already raised once in August. Reuters also reported the third quarter beat and the raised full year profit and sales outlook.

Novo Nordisk beats third quarter and raises outlook

Sources